COMMUNIQUÉS West-GlobeNewswire
 
      -   
  PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes21/10/2025
-   
  Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants21/10/2025
-   
  Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance21/10/2025
-   
  Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation21/10/2025
-   
  XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency21/10/2025
-   
  BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase21/10/2025
-   
  Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy20/10/2025
-   
  Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering20/10/2025
-   
  Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union20/10/2025
-   
  CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer20/10/2025
-   
  SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 202520/10/2025
-   
  BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance20/10/2025
-   
  Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder20/10/2025
-   
  BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase20/10/2025
-   
  Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 202520/10/2025
-   
  Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor20/10/2025
-   
  Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe20/10/2025
-   
  Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)20/10/2025
-   
  Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA20/10/2025
Pages